On December 21, 2023, Shanghai RAAS received the 'Acceptance Notification' from the National Medical Products Administration regarding the clinical trial application for 'SR604 Injection.'

SR604 Injection is a humanized monoclonal antibody that combines with human activated protein C with high affinity and specifically inhibits the anticoagulant function of human activated protein C. It is intended for the prophylactic treatment of bleeding in patients with hemophilia A/B and congenital coagulation factor deficiency.

Currently, routine prophylactic treatment for hemophilia worldwide involves intravenous injection of blood-derived or recombinant coagulation factors 2-3 times a week. SR604 is intended to undergo a Phase I clinical trial for subcutaneous injection prophylactic treatment every 4 weeks. Some preclinical research findings from this project have already been published in the international hematology research journal Blood in the form of a cover article.

As of the disclosed information, there are no products on the global market targeting the same indication as this drug.

'Successful drug development and innovative medicine' has always been the fundamental principle for the growth and establishment of Shanghai RAAS. The company will continue to adhere to the quality policy of 'safety, high quality, and efficiency,' fulfill the brand commitment of 'Shanghai RAAS Health Guardian,' and strive to develop more, better, and innovative drugs for the benefit of society.

https://mp.weixin.qq.com/s/2ca2lJS8-mCJ2M2duWSLVg